# About Peptide Scienes — An Independent Research Peptide File

> About Peptide Scienes: an independent literature file on four unrelated research peptides — CJC-1295, GHK-Cu, semaglutide, and tesamorelin. How it is reported, and what it is not — not a seller, not a clinic, not medical advice.

An independent, citation-anchored look at four unrelated peptides that get marketed under one shared label. Not a vendor. Not a clinic. Not medical advice.

## What Peptide Scienes is

Peptide Scienes is an independent research file covering four peptides — CJC-1295, GHK-Cu, semaglutide, and tesamorelin — chosen specifically because they get discussed under one loose umbrella term, "research peptides," despite belonging to at least three unrelated pharmacological families. The organizing question behind the site is a reporter's question, not a marketing one: what does the actual published evidence say about each of these compounds, and how confidently does it say it?

The answer, it turns out, varies enormously by compound. GHK-Cu leads this desk because its file demonstrates that gap most clearly — deep cell-biology and gene-expression evidence next to a comparatively thin human-trial record outside topical skincare. Semaglutide sits at the opposite extreme, with a clinical-trial program spanning tens of thousands of participants. CJC-1295 and tesamorelin share a receptor and a hormone family but arrived at opposite regulatory fates — one a discontinued research chemical, the other an FDA-approved drug for one specific condition. Reading all four side by side, on the [comparison page](/compare), is the fastest way to see how differently "evidence" can be distributed across compounds that share a marketing category.

## How this file is reported

Three practices govern what appears on this site. First, every research claim traces to a specific citation — peer-reviewed journal articles, clinical-trial publications, regulatory monographs, and reviews, collected with DOIs and PubMed links on the [references page](/references). Second, findings are described at the strength they actually have: a Phase 2 finding is labeled as Phase 2, a rodent or cell-culture result is labeled as such, and an FDA-reviewed trial in one narrow patient population is not generalized beyond that population. Where a compound's file has a documented gap — no long-term safety trial, no head-to-head comparison, no data outside one indication — this file says so directly rather than filling the silence with confidence the evidence does not support.

Third, the four compound pages are cross-linked deliberately, because the same underlying questions recur across all of them: what receptor or pathway is actually engaged, how deep is the human evidence, and what happens once a compound leaves the lab and enters community use. A single shared [references list](/references) aggregates every source cited across all four pages, so no citation appears twice under two different descriptions.

## What it is not

Peptide Scienes is not a pharmacy, clinic, telehealth service, or vendor of any kind. It does not sell, source, or broker CJC-1295, GHK-Cu, semaglutide, tesamorelin, or anything else, and it has no referral or affiliate relationship with any supplier, pharmaceutical company, or telehealth provider. It does not diagnose, prescribe, or recommend a dose, schedule, or route of administration for any person.

Semaglutide and tesamorelin are prescription medicines available only through licensed medical providers. CJC-1295 and GHK-Cu, for any use beyond topical cosmetics, are not approved for human use by any regulatory body. Readers looking for clinical guidance should consult a licensed healthcare provider in their own jurisdiction. Editorial correspondence — citation corrections, newly published studies, out-of-date regulatory information — can be directed to the [contact page](/contact); this file cannot respond to requests for medical advice.

---

An investigative reading file on research peptides — every claim traced to its source, every gap named, revised whenever the record moves.